Cargando…

P910: DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?

Detalles Bibliográficos
Autores principales:	Jingyu, X., Wenqiang, Y., Huishou, F., Jiahui, L., Lingna, L., Chenxing, D., Shuhui, D., Weiwei, S., Yan, X., Lugui, Q., Gang, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430275/ http://dx.doi.org/10.1097/01.HS9.0000846512.25216.bf

Ejemplares similares

Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
por: Xu, Jingyu, et al.
Publicado: (2023)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
por: Liu, Jiahui, et al.
Publicado: (2023)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
por: Yan, Wenqiang, et al.
Publicado: (2023)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Association between the c.910A>G genetic variant of the XRCC1 gene and susceptibility to esophageal cancer in the Chinese Han population
por: Chen, X.Q., et al.
Publicado: (2013)

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
por: Fan, Huishou, et al.
Publicado: (2023)

9,10-Dimethyl-9,10-peroxy-9,10-dihydroanthracene
por: Wang, Yun-Wu
Publicado: (2008)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
por: Liu, Lanting, et al.
Publicado: (2020)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
por: Krzywdzińska, Agnieszka, et al.
Publicado: (2021)

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
por: Anderson, Kenneth C., et al.
Publicado: (2021)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
por: Tapia-Alveal, Claudia, et al.
Publicado: (2020)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

9,10-Diiodophenanthrene
por: Yokota, Ruri, et al.
Publicado: (2012)

9,10-Dibromophenanthrene
por: Yokota, Ruri, et al.
Publicado: (2012)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia
por: Xiong, Wenjie, et al.
Publicado: (2023)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hcimp0vtic9im7dba74n9p77ah